Ngā hua rapu - Christine A. Pratilas

Whakamahine hua
  1. 1
    Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

    Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response mā Christine A. Pratilas, David B. Solit

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Targeting Oncogenic BRAF in Human Cancer

    Targeting Oncogenic BRAF in Human Cancer mā Christine A. Pratilas, Feng Xing, David B. Solit

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor

    From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor mā Kathryn M. Lemberg, Jiawan Wang, Christine A. Pratilas

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors

    BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors mā Karisa C. Schreck, Stuart A. Grossman, Christine A. Pratilas

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    <sup>V600E</sup> BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway

    <sup>V600E</sup> BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway mā Christine A. Pratilas, Barry S. Taylor, Qing Ye, Agnès Viale, Chris Sander, David B. Solit, Neal Rosen

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance

    Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance mā Grazia Ambrosini, Christine A. Pratilas, Li-Xuan Qin, Madhavi Tadi, Oliver Surriga, Richard D. Carvajal, Gary K. Schwartz

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Models from experiments: combinatorial drug perturbations of cancer cells

    Models from experiments: combinatorial drug perturbations of cancer cells mā Sven Nelander, Weiqing Wang, Bengt‐Olof Nilsson, Qing‐Bai She, Christine A. Pratilas, Neal Rosen, Peter Gennemark, Chris Sander

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors

    Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors mā Jiawan Wang, Kai Pollard, Amy N. Allen, Tushar Tomar, Dirk Pijnenburg, Zhan Yao, Fausto J. Rodríguez, Christine A. Pratilas

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Integrated molecular and clinical analysis of BRAF-mutant glioma in adults

    Integrated molecular and clinical analysis of BRAF-mutant glioma in adults mā Karisa C. Schreck, Pinky Langat, Varun Bhave, Taibo Li, E. L. Woodward, Christine A. Pratilas, Charles G. Eberhart, Wenya Linda Bi

    I whakaputaina 2023
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Relapse-free survival in a pediatric patient with recurrent EZH2-mutant melanoma treated with adjuvant tazemetostat

    Relapse-free survival in a pediatric patient with recurrent EZH2-mutant melanoma treated with adjuvant tazemetostat mā Erin E. Resch, Stavriani C. Makri, Paola Ghanem, Ezra Baraban, Kenneth J. Cohen, Alan R. Cohen, Evan J. Lipson, Christine A. Pratilas

    I whakaputaina 2025
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines

    BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines mā Rébecca Leboeuf, Jacqueline E. Baumgartner, Miriam Benezra, Roberta Malaguarnera, David B. Solit, Christine A. Pratilas, Neal Rosen, Jeffrey A. Knauf, James A. Fagin

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition

    3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition mā David B. Solit, Elmer Santos, Christine A. Pratilas, Jose Lobo, Maxim A. Moroz, Shangde Cai, Ronald Blasberg, Judith S. Sebolt‐Leopold, Steven M. Larson, Neal Rosen

    I whakaputaina 2007
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i>-Mutant Lung Cancer

    Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i>-Mutant Lung Cancer mā Erin M. Tricker, Chunxiao Xu, Sharmeen Uddin, Marzia Capelletti, Dalia Ercan, Atsuko Ogino, Christine A. Pratilas, Neal Rosen, Nathanael S. Gray, Kwok‐Kin Wong, Pasi A. Jänne

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies

    Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies mā J. Kyle Bruner, S. Hayley, Li Li, Alice Can Ran Qin, Michelle A. Rudek, Richard J. Jones, Mark J. Levis, Keith W. Pratz, Christine A. Pratilas, Donald Small

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Novel PAX3::MAML3 fusion identified in alveolar rhabdomyosarcoma, using DNA methylation profiling to expand the genetic spectrum of “fusion-positive” cases

    Novel PAX3::MAML3 fusion identified in alveolar rhabdomyosarcoma, using DNA methylation profiling to expand the genetic spectrum of “fusion-positive” cases mā Josephine K. Dermawan, Faizan Malik, John Gross, Ezra Baraban, Christine A. Pratilas, Wadad Mneimneh, Matteo Trucco, Wenyue Sun, Frederic G. Barr, Felipe D’Almeida Costa, Karen Fritchie

    I whakaputaina 2024
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells

    Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells mā Anil Korkut, Weiqing Wang, Emek Demir, Bülent Arman Aksoy, Xiaohong Jing, Evan Molinelli, Özgün Babur, Debra L. Bemis, S. Onur Sumer, David B. Solit, Christine A. Pratilas, Chris Sander

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Size-based detection of sarcoma circulating tumor cells and cell clusters

    Size-based detection of sarcoma circulating tumor cells and cell clusters mā Masanori Hayashi, Peixuan Zhu, Gregory McCarty, Christian F. Meyer, Christine A. Pratilas, Adam S. Levin, Carol D. Morris, Catherine M. Albert, Kyle W. Jackson, Cha-Mei Tang, David M. Loeb

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations

    Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations mā Doreen N. Palsgrove, Yunjie Li, Christine A. Pratilas, Ming‐Tseh Lin, Aparna Pallavajjalla, Christopher D. Gocke, Angelo M. De Marzo, Andrés Matoso, George J. Netto, Jonathan I. Epstein, Pedram Argani

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    BRAF mutation predicts sensitivity to MEK inhibition

    BRAF mutation predicts sensitivity to MEK inhibition mā David B. Solit, Levi A. Garraway, Christine A. Pratilas, Ayana Sawai, Gad Getz, Andrea Basso, Qing Ye, Jose Lobo, Yuhong She, Iman Osman, Todd R. Golub, Judith S. Sebolt‐Leopold, William R. Sellers, Neal Rosen

    I whakaputaina 2005
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

    The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner mā Eric W. Joseph, Christine A. Pratilas, Poulikos I. Poulikakos, Madhavi Tadi, Weiqing Wang, Barry S. Taylor, Ensar Halilovic, Yogindra Persaud, Feng Xing, Agnès Viale, James Tsai, Paul B. Chapman, Gideon Bollag, David B. Solit, Neal Rosen

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: